Trichoscopy is effective for tracking treatment progress in hair loss when used by an experienced doctor.
12 citations
,
January 2018 in “Breast Cancer Basic and Clinical Research” Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
33 citations
,
June 2009 in “Journal of Cutaneous Pathology” Erlotinib can cause nonscarring hair loss and itchy skin.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
OCT can effectively diagnose different stages of hair loss non-invasively.
12 citations
,
June 2019 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
December 2012 in “http://isrctn.org/>”
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
December 2025 in “Journal of Dermatological Treatment” GT20029 helps regrow hair in men with hair loss and is well-tolerated.
The treatment was not recommended due to limited effectiveness and significant side effects.
September 2017 in “Pure and Applied Biology” Chemotherapy and radiotherapy improved quality of life and reduced symptoms in lung cancer patients.
November 2019 in “Neuro-oncology” Rind-based techniques can lower scalp radiation dose and reduce hair loss in brain cancer treatment.
February 2017 in “Cancer Causes & Control” Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
1 citations
,
February 2018 in “Orthopedics and rheumatology” Combining Western chemotherapy with Traditional Chinese Medicine can reduce side effects and improve immune response in treating bone and soft tissue tumors.
4 citations
,
August 2019 in “Actas Dermo-Sifiliográficas” The Spanish HSS-29 scale effectively measures changes in life quality due to female-pattern hair loss.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
5 citations
,
April 2006 in “Skin Research and Technology” Scalp coverage scoring accurately measures hair loss and treatment effectiveness.
148 citations
,
April 2009 in “Molecular Pharmaceutics” Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
December 2013 in “Praxis medica” Using both DLQI and Skindex-16 together gives a better understanding of quality of life in skin disease patients.
April 2023 in “Journal of Investigative Dermatology” An automated system can predict death risk in thin melanoma by analyzing immune cells.
April 2012 in “The Journal of Urology” PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
40 citations
,
April 2006 in “Journal of the European Academy of Dermatology and Venereology” The Trichoscan system was found to be inaccurate for measuring hair growth, needing better software to be useful.
June 2025 in “International Journal of Computational Intelligence Systems” The TPAP method effectively categorizes androgenetic alopecia patients with high accuracy, but needs real-world validation.